X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will accelerate the discovery and development of novel candidates for the treatment of autism, which has seen limited innovation despite remaining an area of major unmet medical need.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Mental Health
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Funding June 03, 2024
Details:
Under the partnership, X-Chem will develop lead candidate, iBRD9, a BRD9 inhibitor, which is an epigenetic reader, as a novel therapeutic target for the treatment of Huntington’s Disease (HD).
Lead Product(s): iBRD9
Therapeutic Area: Genetic Disease Product Name: iBRD9
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: X-Chem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 05, 2023
Details:
Drug candidate demonstrated in vivo proof of concept of a disease modifying effect of bromodomain protein 9 (BRD9) inhibition as a potential treatment for Huntington’s disease (HD).
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
